Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urgently need...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Nyquist, Michael D., Corella, Alexandra, Coleman, Ilsa, De Sarkar, Navonil, Kaipainen, Arja, Ha, Gavin, Gulati, Roman, Ang, Lisa, Chatterjee, Payel, Lucas, Jared, Pritchard, Colin, Risbridger, Gail, Isaacs, John, Montgomery, Bruce, Morrissey, Colm, Corey, Eva, Nelson, Peter S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453577/
https://ncbi.nlm.nih.gov/pubmed/32460015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2020.107669
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados